AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
- Details
Thrombogenics will pay €1 million to Galapagos to further explore integrin antagonists as treatment for diabetic retinopathy.
Read more: Deal struck to develop integrin antagonist treatment
- Details
A new study shows that the new low-add versions of the 1-piece Tecnis multifocal IOL yield greater patient satisfaction and a higher rate of spectacle independence compared to the older +4.00 Tecnis multifocal lens.
Read more: New low-add multifocal IOLs yield higher patient satisfaction
- Details
The companies will jointly develop a combination of the angiopoietin2 antibody nesvacumab and the anti-VEGF aflibercept for the treatment of wet AMD and diabetic macular edema.
Read more: Regeneron, Bayer to develop AMD combination therapy
- Details
Visunex says its PanoCam Pro wide-field imaging system can detect external, anterior and posterior segment vision disorders in newborns.
Read more: FDA approves wide-field imaging system for newborns
- Details
Scientists at the University of Southern California Eye Institute are using advanced retinal imaging combined with comprehensive brain mapping techniques to unlock the mysteries of the brain as it relates to vision loss.
Read more: Brain mapping may someday lead to vision-restoring therapies
- Details
Some eye drop bottles are losing plastic safety seals or tamper evident rings below the bottle cap when consumers tilt or squeeze the bottle as they instill eye drops, causing eye injuries.